DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

934 Leeb-Lundberg LM, Marceau F, Muller-Esterl W, et al.
International union of pharmacology. XLV. Classification of
the kinin receptor family: From molecular mechanisms to
pathophysiological consequences. Pharmacol Rev, 2005,
57:27–77.
Leurs R, Chazot PL, Shenton FC, et al. Molecular and biochemical
pharmacology of the histamine H4 receptor. Br J
Pharmacol, 2009, 157:14–23.
Lewis T. The Blood Vessels of the Human Skin and Their
Responses. London, Shaw and Sons, 1927.
Lim HD, van Rijn RM, Ling P, et al. Evaluation of histamine H 1
-
, H 2
-, and H 3
-receptor ligands at the human histamine H 4
receptor: Identification of 4-methylhistamine as the first potent
and selective H 4
receptor agonist. J Pharmacol Exp Ther,
2005, 314:1310–1321.
Lovenberg TW, Roland BL, Wilson SJ, et al. Cloning and functional
expression of the human histamine H 3
receptor. Mol
Pharmacol, 1999, 55:1101–1105.
Mandle RJ, Colman RW, Kaplan AP. Identification of
prekallikrein and high-molecular-weight kininogen as a complex
in human plasma. Proc Natl Acad Sci U S A, 1976, 73:
4179–4183.
Marcic B, Deddish PA, Jackman HL, Erdös EG. Enhancement of
bradykinin and resensitization of its B 2
receptor. Hypertension,
1999, 33:835–843.
Margolius HS. Theodore Cooper Memorial Lecture. Kallikreins
and kinins: Some unanswered questions about system characteristics
and roles in human disease. Hypertension, 1995,
26:221–229.
Matthews KW, Mueller-Ortiz SL, Wetsel RA. Carboxypeptidase
N: A pleiotropic regulator of inflammation. Mol Immunol,
2004, 40:785–793.
Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine
HCL: A unique therapeutic option in H 1
-receptor antagonist
treatment. J Allergy Clin Immunol, 2003, 112:S29–S37.
Meszaros JG, Gonzalez AM, Endo-Mochizuki Y, et al.
Identification of G protein–coupled pathways in cardiac
fibroblasts: Cross-talk between G q
and G s
. Am J Physiol, 2000,
278:C154–C162.
Morrow JD, Margolies GR, Rowland J, Roberts LJ II. Evidence
that histamine is the causative toxin of scombroid-fish poisoning.
N Engl J Med, 1991, 324:716–720.
Mullol J, Bousquet J, Bachert C, et al. Rupatadine in allergic
rhinitis and chronic urticaria. Allergy, 2008, 63(suppl):
5–28.
Nadel JA, Barnes PJ. Autonomic regulation of the airways. Annu
Rev Med, 1984, 35:451–467.
Oda T, Morikawa N, Saito Y, et al. Molecular cloning and characterization
of a novel type of histamine receptor preferentially
expressed in leukocytes. J Biol Chem, 2000, 275:
36781–36786.
Ondetti MA, Williams NJ, Sabo EF, et al. Angiotensin-converting
enzyme inhibitors from the venom of Bothrops jararaca:
Isolation, elucidation of structure, and synthesis. Biochemistry,
1971, 10:4033–4039.
Paton DM, Webster DR. Clinical pharmacokinetics of H 1
-receptor
antagonists (the antihistamines). Clin Pharmacokinet, 1985,
10:477–497.
Pesquero JB, Bader M. Genetically altered animal models in the
kallikrein-kinin system. Biol Chem, 2006, 387:119–126.
SECTION IV
INFLAMMATION, IMMUNOMODULATION, AND HEMATOPOIESIS
Pfeffer MA, Frohlich ED. Improvements in clinical outcomes
with the use of angiotensin-converting enzyme inhibitors:
Cross-fertilization between clinical and basic investigation.
Am J Physiol Heart Circ Physiol, 2006, 291:H2021–H2025.
Regoli D, Barabe J. Pharmacology of bradykinin and related
kinins. Pharmacol Rev, 1980, 32:1–46.
Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime
sedative effects of H 1
antihistamines. J Clin Psychopharmacol,
2002, 22:511–515.
Rocha e Silva M, ed. Histamine and Anti-Histaminics:
Chemistry, Metabolism and Physiological and Pharmacological
Actions. In: Handbook of Experimental Pharmacology, Vol. 18,
Pt. 2. Berlin, Springer-Verlag, 1978.
Rocha e Silva M, Beraldo WT, Rosenfeld G. Bradykinin, a
hypotensive and smooth muscle stimulating factor released
from plasma globulin by snake venoms and by trypsin. Am J
Physiol, 1949, 156:261–273.
Rothschild AM. Histamine release by basic compounds. In:
Rocha e Silva M, ed. Histamine and Anti-Histamines.
Handbook of Experimental Pharmacology, Vol 18. Berlin,
Springer-Verlag, 1966, pp. 386–430.
Saitoh S, Scicli AG, Peterson E, Carretero OA. Effect of inhibiting
renal kallikrein on prostaglandin E 2
, water, and sodium
excretion. Hypertension, 1995, 25:1008–1013.
Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists
go to clinics. Biol Pharm Bull, 2008, 31:2163–2181.
Sangsree S, Brovkovych V, Minshall RD, Skidgel RA. Kininase
I-type carboxypeptidases enhance nitric oxide production in
endothelial cells by generating bradykinin B 1
receptor agonists.
Am J Physiol Heart Circ Physiol, 2003, 284: H1959–H1968.
Schmaier AH. Assembly, activation, and physiologic influence of
the plasma kallikrein/kinin system. Int Immunopharmacol,
2008, 8:161–165.
Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein
in hereditary angioedema pathogenesis: A clinical trial of
ecallantide, a novel kallikrein inhibitor. J Allergy Clin
Immunol, 2007, 120:416–422.
Schwartz LB. Mast cells: Function and contents. Curr Opin
Immunol, 1994, 6:91–97.
Sick E, Niederhoffer N, Takeda K, et al. Activation of CD47
receptors causes histamine secretion from mast cells. Cell Mol
Life Sci, 2009, 66:1271–1282.
Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine
decreases wheal volume and improves cold provocation
thresholds compared with standard-dose treatment in
patients with acquired cold urticaria: A randomized, placebocontrolled,
crossover study. J Allergy Clin Immunol, 2009,
123:672–679.
Silverberg M, Dunn JT, Garen L, Kaplan AP. Autoactivation of
human Hageman factor. Demonstration utilizing a synthetic
substrate. J Biol Chem, 1980, 255:7281–7286.
Simons SER. Antihistamines. In: Adkinson J, Franklin N,
Younginger JW, et al., eds. Middelton’s Allergy: Principles
and Practice, 6th ed. Philadelphia, Mosby, 2003, pp. 834–869.
Skidgel RA, Erdös EG. Enzymatic degradation of bradykinin.
In: Said SI, ed. Pro-inflammatory and Antiinflammatory
Peptides. New York, Marcel Dekker, 1998, pp. 459–516.
Skidgel RA, Erdös EG. Structure and function of human plasma
carboxypeptidase N, the anaphylatoxin inactivator. Int
Immunopharmacol, 2007, 7:1888–1899.